Anlotinib Retrospective Study for Esophageal Cancer

Completed

• Conditions: Esophageal Neoplasms
• Interventions: Drug: Anlotinib

• Registration Number: NCT05303740
• Lead Sponsor: Feng Wang

Brief Summary

The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-01
• Status Verified: 2022-03
• Primary Completion: 2022-03-01
• Study Completion: 2022-03-01
• Study First Submitted: 2022-03-14
• Study First Submitted QC: 2022-03-27
• Last Update Submitted: 2022-03-27
• Study First Posted: 2022-03-31
• Last Update Posted: 2022-03-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Esophageal cancer diagnosed pathologically or clinically
• Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment

Exclusion Criteria

None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Anlotinib	Anlotinib	-

Primary Outcome Measures

Name	Time	Method
PFS	From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months	Progression Free Survival

Secondary Outcome Measures

Name	Time	Method
OS	From date of admission until the date of death from any cause, assessed up to 24 months	Overall Survival

Trial Locations

Locations (1)

The First Affiliated Hospital of Zhengzhou University; 🇨🇳 Zhengzhou, Henan, China